Transdermal Or Percutaneous Patents (Class 424/449)
-
Patent number: 8747885Abstract: The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation.Type: GrantFiled: December 15, 2004Date of Patent: June 10, 2014Assignees: Teikoku Seiyaku Co., Ltd., Drossapharm AGInventors: Tomohiro Ishima, Hiroyuki Yamasaki, Masahiro Yamaji
-
Patent number: 8747889Abstract: A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.Type: GrantFiled: March 7, 2013Date of Patent: June 10, 2014Assignee: Durect CorporationInventors: Robert M. Gale, Thomas M. Stein, Jay Audett, Jane Stepic, Joseph B. Phipps, Michael J. N. Cormier
-
Patent number: 8747887Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.Type: GrantFiled: October 3, 2005Date of Patent: June 10, 2014Assignee: KCI Medical ResourcesInventor: Arthur C. Coffey
-
Patent number: 8741941Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.Type: GrantFiled: September 22, 2011Date of Patent: June 3, 2014Assignee: Pola Pharma Inc.Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
-
Patent number: 8741331Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: June 12, 2013Date of Patent: June 3, 2014Assignees: A. V. Topchiev Institute of Petrochemicals Synthesis, Russian Academy of Sciences, Corium International, Inc.Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bairamov
-
Patent number: 8741336Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.Type: GrantFiled: June 4, 2012Date of Patent: June 3, 2014Assignee: Chrono Therapeutics, Inc.Inventors: Guy DiPierro, Steven A. Giannos
-
Patent number: 8734838Abstract: A pressure-sensitive adhesive composition which comprises three ingredients, i.e., polyisoprene, a styrene/isoprene/styrene copolymer, and solid polyisobutylene, in a proportion of (10-60)/(10-50)/(20-60) by weight and further contains a non-solid isobutylene polymer and a tackifier, characterized in that the amount of the non-solid isobutylene polymer is 1 to 30 pts. wt., excluding 30 pts. wt., per 100 pts. wt. of the sum of the three ingredients, i.e., the polyisoprene, styrene/isoprene/styrene copolymer, and solid polyisobutylene. When used in an adhesive patch for external use on the skin, the composition has satisfactory tackiness regardless of whether the temperature of the surrounding air is high or low, has excellent long-term storage stability, retains the necessary cohesive force, and does not unnecessarily irritate the skin.Type: GrantFiled: October 20, 2004Date of Patent: May 27, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Masato Shirai, Takaaki Yoshinaga, Masato Wakamatsu
-
Patent number: 8728514Abstract: Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as the water is introduced to the patch from the skin, so that the drug is maintained at the saturation concentration even though the drug content is decreased as the drug is permeated to the skin. During the application of the transdermal preparation to the skin, it is possible to continuously permeate the high amount of drug, to maintain the sufficient adhesion during the use and to minimize the skin side effect, because the hydrophilic polymer absorbs the water from the skin. The hydrophilic polymer system can serve the function thereof through the hydrophobic adhesive layer capable of preventing the water quickly absorbed from the skin from being evaporated to the outside of the patch.Type: GrantFiled: October 23, 2006Date of Patent: May 20, 2014Assignee: Pacific Pharmaceutical Co., Ltd.Inventors: Yang Gyu Choi, Young Chang Ah, Woo Jeong Choi, Jung Ju Kim
-
Patent number: 8728511Abstract: Controlled release melatonin formulations are useful for imparting avoidance of mood depression which may be associated with administration of melatonin in conventional form comprising. Particular embodiments of methods use formulations designed to release melatonin according to a profile that simulates a normal endogenous melatonin nocturnal profile. The methods also include co-administration with additional medicaments.Type: GrantFiled: October 25, 2011Date of Patent: May 20, 2014Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Nava Zisapel, Moshe Laudon
-
Patent number: 8728445Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.Type: GrantFiled: May 1, 2002Date of Patent: May 20, 2014Assignees: A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Corium International, Inc.Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platé, Valery G. Kulichikhin
-
Publication number: 20140134230Abstract: The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use.Type: ApplicationFiled: January 21, 2014Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Theobold Frank, Bettina Wall, Beatrix Platt, Roger Lane
-
Patent number: 8710290Abstract: A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof. In use, the surface having the depressions is disposed adjacent a surface of the wound. A method of manufacturing a therapeutic device for promoting the healing of a wound in a mammal comprising the steps of providing a permeable substrate, and forming a plurality of depressions into a surface of the permeable substrate to provide the therapeutic device. A method of treating a wound comprises: providing a permeable structure comprising a plurality of randomly disposed fibers and having i) a plurality of wound surface contact elements disposed between end portions of the structure, and ii) a plurality of voids defined by the contact elements; and applying the permeable structure to at least one surface of the wound.Type: GrantFiled: July 5, 2012Date of Patent: April 29, 2014Assignee: Boehringer Technologies, L.P.Inventors: John R. Boehringer, John Karpowicz, Amitabha Mitra, Christopher L. Radl
-
Patent number: 8703178Abstract: The present invention relates to a percutaneous administration device of bisoprolol, which includes a backing; and a pressure-sensitive adhesive layer containing bisoprolol, which is laminated on one surface of the backing, wherein the maximum value of a release rate of bisoprolol during a period of from immediately after the application on skin until a lapse of 24 hours is 30 ?g/cm2/hr or less; and wherein the release rate of bisoprolol at the time of a lapse of 24 hours after the application on skin is 10 ?g/cm2/hr or less. The percutaneous administration device of the present invention is reduced in the skin irritation during the application, especially at the time of peeling, and is capable of persistently administrating a therapeutically or preventively effective amount of bisoprolol into a living body.Type: GrantFiled: March 6, 2008Date of Patent: April 22, 2014Assignees: Nitto Denko Corporation, Toa Eiyo Ltd.Inventors: Yoshihiro Iwao, Kensuke Matsuoka, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa
-
Patent number: 8702664Abstract: By providing a non-liquid drug reservoir layer 2 having first and second principal surfaces and containing a drug and a polymer that is to be a base, a drug permeation layer 4 disposed at the first principal surface side of the drug reservoir layer 2 and being lower in permeability of the drug than the drug reservoir layer 2, and a first backing 3 with a bending resistance of 10 to 80 mm that is formed so as to cover a side surface of the drug reservoir layer, skin irritation can be reduced.Type: GrantFiled: February 9, 2010Date of Patent: April 22, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Satoshi Amano, Tomohiro Shinoda, Natsumi Kase, Keita Mori
-
Publication number: 20140105959Abstract: Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising. Devices for reducing or ameliorating adverse events from dermal filler administration are also included.Type: ApplicationFiled: October 10, 2013Publication date: April 17, 2014Applicant: ALLERGAN, INC.Inventors: Sumit Paliwal, Dennis Van Epps
-
Patent number: 8697119Abstract: The present invention relates to medical devices which contain isobutylene copolymers. The present invention also relates to biocompatible copolymer materials for therapeutic agent delivery comprising a therapeutic-agent-loaded isobutylene copolymer. According to an aspect of the present invention, a medical device is provided, which includes: (a) a substrate and (b) at least one polymeric layer, which contains a copolymer, disposed over all or a portion of the substrate. The copolymer contains one or more polymer chains, within which isobutylene and elevated Tg monomers (and, optionally, other monomers) are incorporated in a random, periodic, statistical or gradient distribution.Type: GrantFiled: July 19, 2004Date of Patent: April 15, 2014Assignee: Boston Scientific Scimed, Inc.Inventors: Robert E. Richard, Rudolf Faust
-
Publication number: 20140100537Abstract: The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.Type: ApplicationFiled: December 11, 2013Publication date: April 10, 2014Applicant: MEDICURE INTERNATIONAL INC.Inventors: George Roby THOMAS, Dawson James REIMER, Albert D. FRIESEN
-
Patent number: 8691267Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.Type: GrantFiled: August 7, 2003Date of Patent: April 8, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takaaki Terahara, Kazunosuke Aida, Arata Toshimitsu, Naruhito Higo
-
Patent number: 8691268Abstract: A method for delivery of substance through at least one dermal layer, by providing a substance in microcapsules at a predetermined size, within a medium (150) for holding the microcapsules; placing the medium for holding the microcapsules on a surface of a patch (100) adjacent the skin (320) of a human or animal; and applying energy (200) to the patch, the energy having a characteristic of disturbing the integrity of the microcapsules, thereby resulting in release of the substance from the microcapsules. The energy may be selectively applied to release the substance at desired times. The substance may be a drug or other active agent.Type: GrantFiled: September 15, 2010Date of Patent: April 8, 2014Assignee: Ultra-Sonic Technologies, L.L.C.Inventor: Ludwig J. Weimann
-
Publication number: 20140093555Abstract: The present invention provides a patch preparation containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a drug, amine oxide, a low-polar liquid component based on an organic compound having an angle of 0-19° as calculated by the formula (I): angle(°)=arctan(inorganic value/organic value)×(180/?) and using an inorganic value and an organic value on an organic conceptual diagram, and an adhesive base, and the adhesive layer has an amine oxide content of 0.1-5 wt % and a low-polar liquid component content of 30-50 wt %.Type: ApplicationFiled: September 27, 2013Publication date: April 3, 2014Inventors: Masato NISHIMURA, Yoshitaka INOUE, Yoshiaki ITO
-
Patent number: 8679523Abstract: The present invention comprises methods and compositions for delivery devices. More particularly, the present invention comprises methods and compositions for devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having oxygen and optionally active agents incorporated therein. The matrix may be formed into any desired shape for treatment of compromised tissue or for delivery of oxygen to a localized environment.Type: GrantFiled: December 29, 2000Date of Patent: March 25, 2014Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Bruce L. Gibbins, Lance D. Hopman
-
Patent number: 8673346Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.Type: GrantFiled: May 10, 2013Date of Patent: March 18, 2014Assignee: Chrono Therapeutics, Inc.Inventors: Werner Zumbrunn, Georgios Imanidis, Guy DiPierro, Hans Wernher van De Venn
-
Patent number: 8673335Abstract: Compositions and methods for sealing, coating and adhering tissues are provided that utilize a polymeric system comprising at least a Polymer and a crosslinking agent; and, optionally, (i) a Gelation Disrupting Agent, (ii) an Augmentative Polymer or Monomer, (iii) an Adjunct Compound (iv) an Antimicrobial Agent (v) an Adhesion Enhancer, (vi) a Crosslink Augmentating Agent or any combination thereof. Additionally, a Therapeutic Agent may be incorporated.Type: GrantFiled: September 13, 2007Date of Patent: March 18, 2014Assignee: Southeastern Medical Technologies, LLCInventors: Curtis E. Jones, John P. Kennedy
-
Patent number: 8668925Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 10, 2004Date of Patent: March 11, 2014Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Patent number: 8663680Abstract: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.Type: GrantFiled: December 5, 2011Date of Patent: March 4, 2014Assignee: ALZA CorporationInventor: Robert M. Gale
-
Publication number: 20140056965Abstract: A removable patch configured to be applied over a skin surface, comprises an adhesive layer disposed on the removable patch, and a delivery layer disposed on the removable patch. The delivery layer carries an activating chemical neuromodulator adapted to be transcutaneously applied to afferent A fibers disposed under the skin surface. The delivery layer further carries an inhibiting chemical neuromodulator adapted to be transcutaneously applied to C fibers disposed under the skin surface. A method for treating a patient suffering from a neurological disorder comprises transcutaneously applying an activating chemical neuromodulator over a skin surface adjacent to a trigeminal nerve tissue of the patient, and activating afferent A fibers in the trigeminal nerve, the activation being carried out by the chemical neuromodulator.Type: ApplicationFiled: August 19, 2013Publication date: February 27, 2014Applicant: BOSTON SCIENTIFIC NEUROMODULATION CORPORATIONInventor: Kerry Bradley
-
Patent number: 8652511Abstract: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.Type: GrantFiled: March 30, 2011Date of Patent: February 18, 2014Assignee: Phosphagenics LimitedInventors: Jeremy Cottrell, Giacinto Gaetano, Mahmoud El-Tamimy, Nicholas Kennedy, Paul David Gavin
-
Patent number: 8647664Abstract: A patch preparation having a backing layer and a drug layer laminated on the backing layer; wherein the drug layer contains an adhesive containing at least one compound selected from the group consisting of fentanyl and pharmaceutically acceptable salts thereof, polyisobutylene, and a silicon-containing polymer; and a mass ratio of the polyisobutylene and the silicon-containing polymer in the adhesive is 20:1 to 7:3.Type: GrantFiled: June 27, 2007Date of Patent: February 11, 2014Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Sachiko Honma, Tetsuro Tateishi
-
Patent number: 8647665Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: August 13, 2012Date of Patent: February 11, 2014Assignee: Antares Pharma IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Patent number: 8647647Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.Type: GrantFiled: July 21, 2010Date of Patent: February 11, 2014Assignee: Aidance Skincare and Topical Solutions, LLCInventor: Perry Antelman
-
Patent number: 8641691Abstract: A portable system for subatmospheric pressure therapy in connection with healing a surgical wound, includes a wound dressing dimensioned for positioning relative to a wound bed of a subject, a portable subatmospheric pressure mechanism dimensioned to be carried or worn by the subject and a container for collecting exudates from the wound bed removed under the subatmospheric pressure supplied by the subatmospheric pressure mechanism. The portable subatmospheric pressure mechanism includes a housing, a subatmospheric pressure source disposed within the housing and in fluid communication with the wound dressing to supply subatmospheric pressure to the wound dressing and a power source mounted to or within the housing for supplying power to actuate the subatmospheric pressure source.Type: GrantFiled: September 27, 2007Date of Patent: February 4, 2014Assignee: Smith & Nephew, Inc.Inventors: David Fink, David Heagle, Sharon A. Mulligan
-
Publication number: 20140030316Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicant: ALZA CorporationInventors: Subramanian S. Venkatraman, Shaoling Li, Robert M. Gale, Jane Stepic, William W. Van Osdol
-
Patent number: 8637073Abstract: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.Type: GrantFiled: July 26, 2004Date of Patent: January 28, 2014Assignee: Purdue Pharma L.P.Inventors: Bruce E. Reidenberg, Daniel A. Spyker
-
Patent number: 8632759Abstract: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic acid or its salt or its derivative, and a composition containing iron sodium diethylenetriaminepentaacetate or iron ammonium diethylenetriaminepentaacetate as active components, a hair restorer and a method for restoring hair which are excellent in hair growth promotion, and stability and safety, are provided.Type: GrantFiled: January 27, 2012Date of Patent: January 21, 2014Assignee: Cosmo Oil Co., Ltd.Inventor: Yoshiyasu Ito
-
Patent number: 8633159Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.Type: GrantFiled: March 2, 2010Date of Patent: January 21, 2014Assignee: Alza CorporationInventors: Mahmoud Ameri, Michel J. N. Cormier, Yuh-Fun Maa, Marika Kamberi, Peter E. Daddona
-
Patent number: 8632512Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.Type: GrantFiled: April 9, 2010Date of Patent: January 21, 2014Assignee: KCI Licensing, Inc.Inventors: Dmitry Zimnitsky, Jenny Finkbiner, Blane Sanders
-
Patent number: 8632801Abstract: Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.Type: GrantFiled: December 28, 2006Date of Patent: January 21, 2014Assignee: Alza CorporationInventors: Mahmoud Ameri, Michel J. N. Cormier, Scott Sellers, Yuh-Fun Maa
-
Patent number: 8632802Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.Type: GrantFiled: September 9, 2011Date of Patent: January 21, 2014Assignee: Noven Pharmaceuticals, Inc.Inventor: David Kanios
-
Patent number: 8632800Abstract: A multilayered drug delivery system with a barrier suitable for delivery of drug through an individual's body surface. By placing a barrier between two adjacent layers, unintended drug flow due to migration of a drug matrix between the adjacent matrix layers in the system to a patient is avoided.Type: GrantFiled: May 12, 2006Date of Patent: January 21, 2014Assignee: ALZA CorporationInventors: Rolf R. Jansen, Dina J. Coronado
-
Patent number: 8628795Abstract: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterized in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.Type: GrantFiled: August 18, 2010Date of Patent: January 14, 2014Assignee: LTS Lohmann Therapie-Systeme AGInventors: Thomas Hille, Lothar Deurer
-
Publication number: 20140010860Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.Type: ApplicationFiled: May 12, 2006Publication date: January 9, 2014Inventors: Isa Odidi, Amina Odidi
-
Patent number: 8623404Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.Type: GrantFiled: February 28, 2011Date of Patent: January 7, 2014Assignee: Watson Laboratories, Inc.Inventor: Michael W. Kimball
-
Patent number: 8623387Abstract: Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance. The external preparation composition can be used as a liquid preparation, an ointment, a cream, a plaster or the like, and enables to provide a preparation having excellent transdermal absorbability.Type: GrantFiled: November 20, 2008Date of Patent: January 7, 2014Assignee: Medrx Co., Ltd.Inventors: Toshikazu Yamaguchi, Kenta Kawai, Katsuhiro Yamanaka, Noboru Tatsumi
-
Publication number: 20140005617Abstract: Provided is a fentanyl transdermal patch comprising an acrylic-rubber hybrid as a drug-adhesive layer. The fentanyl transdermal patch can maintain constant fentanyl skin permeability for three days by maintaining close contact with the skin such that desorption, release by moisture and sweat, and skin stimulation are all improved.Type: ApplicationFiled: March 13, 2012Publication date: January 2, 2014Inventors: Young Kwen Choi, Jung Ju Kim, Jung Sik Lee, Sung Soo Kim
-
Patent number: 8617591Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.Type: GrantFiled: April 27, 2012Date of Patent: December 31, 2013Assignee: UCB Pharma GmbHInventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
-
Patent number: 8617590Abstract: A method of increasing strength using a nutrient holding device (pedal device, hat band, necklace, locket, belt, etc.) which contains at least one nutrient which has the ability to stimulate reflex zones on the skin resulting in improved performance when worn during athletic endeavors (exercise).Type: GrantFiled: November 25, 2002Date of Patent: December 31, 2013Inventor: Edward Ludwig Blendermann
-
Patent number: 8614274Abstract: A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin.Type: GrantFiled: January 11, 2011Date of Patent: December 24, 2013Assignee: Mylan Technologies Inc.Inventors: Kristin Jackson, Kenneth James Miller, II
-
Patent number: 8609134Abstract: Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that find use in practicing the subject methods.Type: GrantFiled: September 8, 2010Date of Patent: December 17, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Kunio Yoneto, Katsuyuki Inoo
-
Publication number: 20130331803Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.Type: ApplicationFiled: November 17, 2010Publication date: December 12, 2013Applicant: HEXAL AGInventors: Jens Fleschhut, Susanne Feinaeugle, Karin Lauer
-
Patent number: 8597667Abstract: A system and methods are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. The captured image data is then analyzed by a computing device to generate a unique skin profile for the user. Based on such skin profile, a printing device prints out one or more cosmetic delivery sheets that can be applied to the predetermined treatment area. Each of the cosmetic delivery sheets contains a substrate with multiple isolated, discrete regions, while at least two of the regions are imprinted with different skin benefit agents for treating different skin conditions of the predetermined treatment area according to the unique skin profile of the user.Type: GrantFiled: March 24, 2009Date of Patent: December 3, 2013Assignee: ELC Management LLCInventors: Tsung-Wei Robert Mou, Fatemeh Mohammadi, Lisa Qu, Tamar Lara Kamen, Anna Czarnota